Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Centene CNC in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 7 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 4 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 2 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $92.36, a high estimate of $110.00, and a low estimate of $82.00. A 1.35% drop is evident in the current average compared to the previous average price target of $93.62.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Centene is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Ha | Baird | Announces | Neutral | $83.00 | - |
| Andrew Mok | Barclays | Raises | Overweight | $104.00 | $101.00 |
| George Hill | Deutsche Bank | Raises | Hold | $82.00 | $81.00 |
| Michael Wiederhorn | Oppenheimer | Maintains | Outperform | $110.00 | $110.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $93.00 | $89.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $89.00 | $94.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $90.00 | - |
| Scott Fidel | Stephens & Co. | Lowers | Equal-Weight | $85.00 | $92.00 |
| Scott Fidel | Stephens & Co. | Lowers | Equal-Weight | $85.00 | $92.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $94.00 | $90.00 |
| Andrew Mok | Barclays | Announces | Overweight | $101.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Centene. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Centene compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Centene's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Centene's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Centene analyst ratings.
Discovering Centene: A Closer Look
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
A Deep Dive into Centene's Financials
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 3.9%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Centene's net margin is impressive, surpassing industry averages. With a net margin of 2.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Centene's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.41%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.39%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 0.67, Centene faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Core of Analyst Ratings: What Every Investor Should Know
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
